abstract |
The present invention has the general formula I, wherein the groups R 1 , R 2 and m have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity, as defined in claim 1, It relates to the compound (I). This compound is suitable for the treatment and prevention of diseases that can be affected by this receptor, for example metabolic diseases, in particular type 2 diabetes. I |